Ibogaine Shows Promise as a Treatment for Addiction

Addiction sits at the meeting point of biology and psychology, and it rarely stays in one lane. Dr. Gabor Maté has argued that the standard Western approach misses much of what keeps people dependent: the spiritual and emotional pain sitting beneath the physical symptoms. Part of why treatment falls short, he suggests, comes from how quickly and carelessly we have filed away certain substances as purely dangerous and medically worthless.

Ibogaine is one of those filed-away substances. It is a psychoactive alkaloid that occurs naturally in Iboga, a shrub native to West Africa. Iboga and its derivative ibogaine have long been central to the Bwiti religion, and communities across Africa have used the plant in healing and initiation rites. Its Schedule I status in the United States has made serious research into its effect on heroin addiction difficult to carry out.

Despite that, years of personal accounts kept pointing in the same direction: that ibogaine has something real to offer addiction treatment. The weight of those accounts was eventually enough to push at least two academic studies forward. The findings are early, and far more work is needed before anyone can speak with certainty, but they read as an invitation to keep asking questions rather than a closed case.

The first hint came by accident. In 1962 Howard Lotsof, a heroin user looking for a new kind of high, took ibogaine and found afterward that he could stop using heroin. That surprise reshaped the rest of his life; he spent much of it pushing for scientific study of ibogaine as a possible treatment for opiate dependence. Dr. Andrew Weil has described how Lotsof teamed up with a Dutch psychiatrist to build an ibogaine-assisted therapy program. Of the 30 addicts they worked with, two thirds managed to stay off opiates for stretches running from four months to four years. If those numbers hold up under more rigorous testing, they would mark a large improvement over conventional treatment, where relapse rates sit around 75 percent.

Lotsof was not alone in calling ibogaine a genuine healing tool. Dimitri Mugianis, also based in New York, credits ibogaine with ending a heroin habit that had lasted twenty years. After getting clean, he began guiding other New York users through their own sessions, working as something close to a shaman in rented hotel rooms. That work caught up with him legally: he was convicted of a felony in 2001 and could no longer supply ibogaine to the people he wanted to reach. He has since travelled repeatedly to Gabon, where he was initiated into the Bwiti religion, and he brings its healing practices of music and dance back to heroin users in the States.

What Mugianis describes is a hybrid. He pictures a kind of ceremonial detox, pairing the ritual side of African healing with the safety net of a Western medical team watching over the patient. Beyond its Schedule I label, he points to another reason the substance has stayed understudied: a naturally occurring compound cannot be patented, which leaves little financial incentive for pharmaceutical companies to fund the research.

One of the formal studies took place at an ibogaine clinic in Baja California, Mexico, run by Dr. Tom Kingsley Brown of the University of California, San Diego, alongside Valerie Mojeiko of MAPS. The researchers wanted to see whether ibogaine-assisted therapy could produce extended periods of opiate abstinence, cut overall heroin use, and soften the damage that addiction-driven behavior leaves behind. They also looked at whether the therapy eased symptoms of depression and whether it shifted emotional intelligence in a positive direction.

Under monitored conditions, the therapy showed no meaningful risks or adverse effects. The abstinence numbers were modest. Of 30 participants, a third relapsed within the first month, and only four stayed off heroin for more than a year after a single treatment. On paper that reads as a low success rate, yet several other threads from the study argue for pressing on. Many participants said the sessions gave them access to the buried reasons they had started using in the first place. Some described a sweeping sense of amazement, a feeling of moving through stages of their own evolution.

Those reports suggest a deep form of introspection, the kind that can reveal why a person reaches for the temporary relief that heroin offers. Seeing one's small place in the universe, held up against a glimpse of something limitless inside oneself, can be a powerful thing to sit with. The study groups this under the heading of emotional intelligence, which is part of why measuring it matters in any attempt to treat heroin addiction.

The second study came from New Zealand, led by Dr. Geoff Noller, who set out to build a model of heroin treatment that reflected recent changes in drug policy. His work cites clinical accounts of ibogaine's effects, including the way it can surface repressed memories, let people reframe them, and fold that new understanding back into who they are. New Zealand changed its law on ibogaine in 2010. The accumulating evidence, both anecdotal and scientific, kept showing a substance with little recreational appeal, lower mortality and fewer adverse effects than methadone, and, in mouse studies, a capacity to blunt the pain of withdrawal. On that basis the law was loosened to permit further clinical research.

Noller's team wants a holistic treatment, one with support programs and peer-staffed needle exchanges, built on understanding and compassion rather than the usual stigma around drug use. Making ibogaine available by prescription opens the door to that: teams of doctors and psychologists who can carry patients through recovery on the strength of real relationships. New Zealand's approach reflects a healthier way for society to confront addiction. Legalizing ibogaine handles only a sliver of the larger job, but it is a necessary first move toward treatment that reaches the emotional and psychological roots of dependency. Heroin is famously hard to leave behind once a person uses it to fill some inner absence, a difficulty its high relapse rates make plain. Reaching and helping people is the whole point of ibogaine-assisted therapy.

As for the session itself, the website Choose Help lays out what tends to happen during an ibogaine-assisted treatment. The experience moves through distinct phases, each carrying its own value for the healing process. The trip runs anywhere from sixteen to 24 hours, and some break it into three parts. It opens with a dream-like state full of hallucinations, many of them pulled straight from personal memory. Then comes what is often called the evaluative stage, when people report sitting heavily with what they have seen.